-
Product Insights
Febrile Neutropenia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
GlobalData's clinical trial report, “Febrile Neutropenia - Global Clinical Trials Review, 2024" provides an overview of Febrile Neutropenia Clinical trials scenario. This report provides top line data relating to the clinical trials on Febrile Neutropenia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Tourette Syndrome Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Tourette Syndrome Clinical Trial Report Overview A total of 185 Tourette Syndrome clinical trials were conducted as of December 2024. The Tourette Syndrome clinical trial report offers a comprehensive understanding of disease clinical trials across regions, and countries (G7 & E7). It also provides insights into the various phases, trial status, and end points status. Furthermore, the Tourette Syndrome clinical research includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions · Asia-Pacific · ...
-
Product Insights
Rare Disease - Clinical Trials Landscape
Understand the clinical trial landscape of rare disease trials. Identify key analysis and segmentation of these trials by phase, single versus multinational trials, geography, sponsor type (industry versus non-industry), therapy area, indication, top sponsors, drug type, and DCT use.
-
Sector Analysis
Type 1 Diabetes in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033
This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the type 1 diabetes market through 2033. GlobalData estimates sales of T1D therapeutics to be approximately $2.83 billion across the 7MM in 2023. By 2033, GlobalData expects the T1D market to grow at a strong compound annual growth rate (CAGR) of 13.3%, reaching sales of $9.91 billion by the end of the forecast period. Major drivers of T1D market growth over...
-
Sector Analysis
B-cell Depletion - Innovation Insights, Competitive Analysis, Patents, Drugs, Clinical Trials and Deals
B-Cell Depletion Report Overview B cell depletion is a therapeutic strategy to reduce the number of B lymphocytes, which play a crucial role in autoimmune diseases and certain cancers. The approach primarily treats conditions like rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus. Furthermore, the underlying patent publication growth shows an accelerating innovation trend within this field. Big pharma dominates the patent activity followed by private companies, startups, and small biotech. B-cell depletion is an accelerating innovation among 80+ innovation...
-
Sector Analysis
Anti-sense Oligonucleotides - Innovation Insights, Competitive Analysis, Patents, Drugs, Clinical Trials and Deals
Anti-Sense Oligonucleotides Market Report Overview Antisense oligonucleotides (ASO) are a class of biological medicine employed to alter the expression of mRNA and genes using various mechanisms to deliver therapeutic effects. Based on the patent bibliographic metrics, technology foresight identifies ASOs as high-impact innovations in the near term. Asia and North America have the highest drug development activity in anti-sense oligonucleotides. Furthermore, it is an accelerating innovation among 80+ innovations in the pharma industry according to the innovation s-curve framework. Innovation...
-
Sector Analysis
Engineered Multispecific antibodies - Innovation Insights, Competitive Analysis, Patents, Drugs, Clinical Trials and Deals
Engineered Multispecific Antibodies Report Overview Multi-specific antibodies that are engineered to recognize two or more epitopes located on the same or distinct targets are a high-impact innovation and will continue to remain so in the near-term. Engineered multi-specific antibodies is an accelerating innovation among 80+ key innovation areas in the pharma industry according to the innovation s-curve framework. Innovation S-Curve – Innovation Areas Buy the Full Report for More Engineered Multispecific Antibodies Innovation Insights, Download a Free Report Sample Engineered...
-
Sector Analysis
Alzheimer’s Disease (AD) Epidemiology Analysis and Forecast to 2033
Alzheimer’s Disease (AD) Report Overview In the 8MM, there were 15,987,619 total prevalent cases of Alzheimer’s disease (AD) in 2023. The total prevalent cases of AD will register an AGR of more than 4% during 2023-2033. Alzheimer’s disease (AD) is a progressive neurodegenerative disorder marked by cognitive and behavioral impairment that significantly interferes with social and occupational functioning. It is typically characterized by memory loss, cognitive impairment, functional decline, and gradual inability in performing daily tasks independently. Although the exact...
-
Sector Analysis
Glaucoma in 68 Markets - Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2032
Glaucoma Market Report Overview The glaucoma market size across the 68M was $3.1 billion in 2023. The “Glaucoma in 68 Markets” research report covers the 68 geographical markets and provides an Excel-based forecast model for the market through 2033. Glaucoma Market Outlook, 2023-2033 ($ Billion) Buy the Full Report for More Insights on the Glaucoma Market Report Forecast Download a Free Report Sample The Glaucoma market report contains patient-based forecast sales data for the seven major markets (7MM: US, France,...
-
Sector Analysis
Glaucoma in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2031
Glaucoma Market Report Overview The Glaucoma market sales across the 7MM was $2.1 billion in 2023. The sales of glaucoma therapeutics across the 7MM will grow at a compound annual growth rate (CAGR) of more than 2% between 2023 and 2033. Factors such as the surge in the prevalence of glaucoma due to the ageing population and the launch of new products addressing the unmet needs in glaucoma treatment will drive growth in the glaucoma market across the 7MM. Glaucoma...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.